A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
Recruiting in Palo Alto (17 mi)
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Recruiting
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
No Placebo Group
Trial Summary
What is the purpose of this trial?
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-1681 for injection in patients with advanced solid tumors.
Research Team
Eligibility Criteria
Inclusion Criteria
I agree to join the trial and will sign the consent form.
My doctor expects me to live for at least 3 more months.
My cancer is advanced, cannot be surgically removed, and does not respond to standard treatments.
See 3 more
Treatment Details
Participant Groups
1Treatment groups
Experimental Treatment
Group I: SHR-1681Experimental Treatment1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Lead Sponsor
Trials
65
Recruited
15,600+
Dr. Tian Guanghui
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Chief Executive Officer since 2020
PhD in Chemical Engineering
Dr. Shen
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Chief Medical Officer since 2013
MD